Table 2. A comparison of the change in renal function* between study groups.
| Tenofovir (n = 37) | Telbivudine (n = 42) | Entecavir (n = 62) | Total (n = 141) | Mortality※ (n = 7) | |
|---|---|---|---|---|---|
| Certain rise | 0 | 4 (9.5%) | 0 | 4 (2.8%) | 1 (25%) |
| Uncertain rise | 1 (2.7%) | 1 (2.4%) | 1 (1.6%) | 3 (2.1%) | 1 (33.3%) |
| Stable | 34 (91.9%) | 32 (76.2%) | 57 (91.9%) | 123 (87.2%) | 4 (3.3%) |
| Uncertain drop | 1 (2.7%) | 2 (4.8%) | 4 (6.5%) | 7 (5%) | 0 |
| Certain drop | 1 (2.7%) | 3 (7.1%) | 0 | 4 (2.8%) | 1 (25%) |
*The groups for the change in kidney function were defined as: certain rise: rise in CKD category with ≧25% increase in eGFR; uncertain rise: rise in CKD category with <25% rise in eGFR; stable: no change in CKD category; uncertain drop: drop in CKD category with <25% decrease in eGFR; certain drop: drop in CKD category with ≧25% decrease in eGFR.
※All subjects died due to liver cirrhotic complications.